NovoCure Limited (NASDAQ:NVCR) CEO Asaf Danziger sold 15,866 shares of NovoCure Limited stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $22.01, for a total value of $349,210.66. Following the completion of the transaction, the chief executive officer now directly owns 774,040 shares of the company’s stock, valued at $17,036,620.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Asaf Danziger also recently made the following trade(s):

  • On Monday, September 25th, Asaf Danziger sold 900 shares of NovoCure Limited stock. The shares were sold at an average price of $22.05, for a total value of $19,845.00.
  • On Wednesday, September 13th, Asaf Danziger sold 35,500 shares of NovoCure Limited stock. The shares were sold at an average price of $22.01, for a total value of $781,355.00.
  • On Thursday, September 14th, Asaf Danziger sold 37,272 shares of NovoCure Limited stock. The shares were sold at an average price of $22.01, for a total value of $820,356.72.

NovoCure Limited (NASDAQ:NVCR) last announced its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.07. NovoCure Limited had a negative return on equity of 57.68% and a negative net margin of 47.45%. The firm had revenue of $50.10 million for the quarter, compared to analyst estimates of $43.45 million. During the same period last year, the firm posted ($0.39) earnings per share. The business’s revenue for the quarter was up 130.9% on a year-over-year basis.

COPYRIGHT VIOLATION NOTICE: “NovoCure Limited (NVCR) CEO Asaf Danziger Sells 15,866 Shares” was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/02/novocure-limited-nvcr-ceo-asaf-danziger-sells-15866-shares.html.

Several hedge funds have recently made changes to their positions in NVCR. Goldman Sachs Group Inc. boosted its stake in shares of NovoCure Limited by 6,617.7% during the second quarter. Goldman Sachs Group Inc. now owns 4,988,007 shares of the medical equipment provider’s stock valued at $86,293,000 after purchasing an additional 4,913,755 shares in the last quarter. FMR LLC boosted its stake in shares of NovoCure Limited by 50.4% during the second quarter. FMR LLC now owns 6,888,120 shares of the medical equipment provider’s stock valued at $119,165,000 after purchasing an additional 2,309,559 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of NovoCure Limited by 40.5% during the second quarter. Vanguard Group Inc. now owns 4,283,862 shares of the medical equipment provider’s stock valued at $74,111,000 after purchasing an additional 1,235,922 shares in the last quarter. Frontier Capital Management Co. LLC acquired a new stake in shares of NovoCure Limited during the second quarter valued at about $14,308,000. Finally, PointState Capital LP acquired a new stake in shares of NovoCure Limited during the second quarter valued at about $5,744,000. 36.20% of the stock is currently owned by hedge funds and other institutional investors.

A number of research analysts recently issued reports on the company. Zacks Investment Research raised NovoCure Limited from a “hold” rating to a “buy” rating and set a $22.00 price target for the company in a report on Tuesday. Wedbush reissued an “outperform” rating and set a $25.00 price objective (down from $29.00) on shares of NovoCure Limited in a report on Friday, October 27th. Mizuho initiated coverage on NovoCure Limited in a report on Wednesday, September 6th. They set a “buy” rating and a $25.00 price objective for the company. BidaskClub raised NovoCure Limited from a “buy” rating to a “strong-buy” rating in a report on Monday, July 31st. Finally, Deutsche Bank AG reissued a “hold” rating and set a $19.00 price objective (up from $18.00) on shares of NovoCure Limited in a report on Monday, July 17th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $21.00.

About NovoCure Limited

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

Insider Buying and Selling by Quarter for NovoCure Limited (NASDAQ:NVCR)

Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with MarketBeat.com's FREE daily email newsletter.